Prognostic factors for pure ovarian immature teratoma and the role of adjuvant chemotherapy in stage I diseases

References

• Gatta G, van der Zwan JM, Casali PG, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011;47(17):1–9. doi:10.1016/j.ejca.2011.08.008.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Morice P, Lorusso D, et al. Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv1–iv18. doi:10.1093/annonc/mdy001.
   PubMed Web of Science ®Google Scholar
• Smith HO, Berwick M, Verschraegen CF, et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006;107(5):1075–1085. doi:10.1097/01.AOG.0000216004.22588.ce.
   PubMed Web of Science ®Google Scholar
• Park M, Lim J, Lee JA, et al. Incidence and outcomes of malignant ovarian germ cell tumors in korea, 1999-2017. Gynecol Oncol. 2021;163(1):79–84. doi:10.1016/j.ygyno.2021.07.037.
   PubMed Web of Science ®Google Scholar
• Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296. doi:10.3322/caac.21456.
   PubMed Web of Science ®Google Scholar
• Mangili G, Sigismondi C, Lorusso D, et al. The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study. Ann Oncol. 2017;28(2):333–338. doi:10.1093/annonc/mdw563.
   PubMed Web of Science ®Google Scholar
• Murugaesu N, Schmid P, Dancey G, et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol. 2006;24(30):4862–4866. doi:10.1200/JCO.2006.06.2489.
   PubMed Web of Science ®Google Scholar
• Mangili G, Sigismondi C, Gadducci A, et al. Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study. Int J Gynecol Cancer. 2011;21(8):1414–1421. doi:10.1097/IGC.0b013e3182236582.
   PubMed Web of Science ®Google Scholar
• Patterson DM, Murugaesu N, Holden L, et al. A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites. Int J Gynecol Cancer. 2008;18(1):43–50. doi:10.1111/j.1525-1438.2007.00969.x.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian cancer, version 2.2020. J Natl Compr Canc Netw. 2021;19(2):191–226. doi: 10.6004/jnccn.2021.0007.
   PubMed Web of Science ®Google Scholar
• Wang D, Zhu S, Jia C, et al. Role of staging surgery and adjuvant chemotherapy in adult patients with apparent stage I pure immature ovarian teratoma after fertility-sparing surgery. Int J Gynecol Cancer. 2020;30(5):664–669. doi:10.1136/ijgc-2019-001116.
   PubMed Web of Science ®Google Scholar
• Bergamini A, Sarwar N, Ferrandina G, et al. Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis. Eur J Cancer. 2020;137:136–143. doi:10.1016/j.ejca.2020.06.033.
   PubMed Web of Science ®Google Scholar
• Mangili G, Giorda G, Ferrandina G, et al. Surveillance alone in stage I malignant ovarian germ cell tumors: a MITO (multicenter Italian trials in ovarian cancer) prospective observational study. Int J Gynecol Cancer. 2021;31(9):1242–1247. doi:10.1136/ijgc-2021-002575.
   PubMed Web of Science ®Google Scholar
• Newton C, Murali K, Ahmad A, et al. A multicentre retrospective cohort study of ovarian germ cell tumours: evidence for chemotherapy de-escalation and alignment of paediatric and adult practice. Eur J Cancer. 2019;113:19–27. doi:10.1016/j.ejca.2019.03.001.
   PubMed Web of Science ®Google Scholar
• Pavone R, Dijoud F, Galmiche L, et al. Pure pediatric ovarian immature teratomas: the French experience. Pediatr Blood Cancer. 2020;67(4):e28186.
   PubMed Web of Science ®Google Scholar
• Li S, Wang Y, Zhang X, et al. Role of adjuvant chemotherapy in stage I pure ovarian immature teratoma: a systematic review and meta-analysis. Cancers. 2023. doi:10.3390/cancers15061741.
   Web of Science ®Google Scholar
• Jorge S, Jones NL, Chen L, et al. Characteristics, treatment and outcomes of women with immature ovarian teratoma, 1998-2012. Gynecol Oncol. 2016;142(2):261–266. doi:10.1016/j.ygyno.2016.05.024.
   PubMed Web of Science ®Google Scholar
• International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. International germ cell cancer collaborative group. J Clin Oncol. 1997;15(2):594–603.
   PubMed Web of Science ®Google Scholar
• Meisel JL, Woo KM, Sudarsan N, et al. Development of a risk stratification system to guide treatment for female germ cell tumors. Gynecol Oncol. 2015;138(3):566–572. doi:10.1016/j.ygyno.2015.06.029.
   PubMed Web of Science ®Google Scholar
• Pashankar F, Hale JP, Dang H, et al. Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the malignant germ cell tumor international collaborative. Cancer. 2016;122(2):230–237. doi:10.1002/cncr.29732.
   PubMed Web of Science ®Google Scholar
• Yuksel D, Ayhan S, Korkmaz V, et al. Retrospective analysis of pure ovarian immature teratoma in patients aged 15–39 years: a Turkish multicenter study. J Adolesc Young Adult Oncol. 2021;10(6):697–702. doi:10.1089/jayao.2020.0155.
   PubMed Web of Science ®Google Scholar
• Graham R, MacDonald ND, Lockley M, et al. Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: a UK multicentre retrospective cohort study. Eur J Obstet Gynecol Reprod Biol. 2022;271:138–144. doi:10.1016/j.ejogrb.2022.02.013.
   PubMed Web of Science ®Google Scholar
• Nasioudis D, Frey MK, Chapman-Davis E, et al. Surveillance only for high-risk FIGO stage IA/IB malignant ovarian germ cell tumors: results from a national cancer database. Am J Clin Oncol. 2021;44(5):195–199. doi:10.1097/COC.0000000000000805.
   PubMed Web of Science ®Google Scholar
• Liu Q, Ding X, Yang J, et al. The significance of comprehensive staging surgery in malignant ovarian germ cell tumors. Gynecol Oncol. 2013;131(3):551–554. doi:10.1016/j.ygyno.2013.08.016.
   PubMed Web of Science ®Google Scholar